Assignee
BEAM THERAPEUTICS INC
US·14 granted patents·71 pending applications·37 citations·filing 2019–2025
Top patents by PatentIndex Score
85 records- 0196US11344609B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2021·Granted May 31, 2022·6 cites·34 claims
- 0296US11142760B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2021·Granted Oct 12, 2021·14 cites·30 claims
- 0395US11752202B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2022·Granted Sep 12, 2023·3 cites·28 claims
- 0493US2026061041A1Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0592US11155803B2Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2020·Granted Oct 26, 2021·13 cites·30 claims
- 0681US12016908B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2022·Granted Jun 25, 2024·0 cites·14 claims
- 0779US2025025573A1Novel rna base editing compositions, systems, methods and uses thereofBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0878US12133884B2Methods of substituting pathogenic amino acids using programmable base editor systemsBEAM THERAPEUTICS INC·Filed 2019·Granted Nov 5, 2024·1 cites·4 claims
- 0976US2025108098A1Methods of substituting pathogenic amino acids using programmable base editor systemsBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1076US2024132867A1Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1175US12296053B2Nanomaterials comprising triolsBEAM THERAPEUTICS INC·Filed 2024·Granted May 13, 2025·0 cites·26 claims
- 1273US2025144149A1Adenosine deaminase base editors and methods for use thereofBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1370US2022235347A1Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1469US2024327813A1Crispr enzymes, methods, systems and uses thereofBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1569US2024158775A1Adenosine deaminase variants and uses thereofBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1668US2025041441A1NanomaterialsBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1768US2024327802A1Chimeric pseudotyped recombinant rabies virusBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1867US2025108132A1Compositions and methods for reducing complement activationBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1967US2024252550A1Genetic modification of hepatocytesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2066US2025090585A1Modified regulatory t cells and methods of using the sameBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2166US2025288690A1Rna base editing compositions, systems, methods and uses thereofBEAM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2265US2023270840A1Viral guide rna deliveryBEAM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2364US2024325533A1Modified immune cells and methods of using the sameBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2464US2024124536A1Base editing of transthyretin geneBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2563US2024376468A1CIRCULAR GUIDE RNAs FOR CRISPR/CAS EDITING SYSTEMSBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2662US2024132868A1Compositions and methods for the self-inactivation of base editorsBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2762US2024117345A1Compositions and methods for treating transthyretin amyloidosisBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2862US2022290164A1Recombinant rabies viruses for gene therapyBEAM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2962US2024335516A1Compositions and methods for the treatment of spinal muscular atrophy (sma)BEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3061US12268753B2Nanomaterials comprising a biodegradable featureBEAM THERAPEUTICS INC·Filed 2022·Granted Apr 8, 2025·0 cites·14 claims
- 3161US2024358841A1Nanomaterials comprising tetravalent lipid compoundsBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3261US2025102524A1Hemoglobin g-makassar binding polypeptides and antibodies and methods of using the sameBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3361US2024335542A1Nanomaterials comprising disulfidesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3461US2024335543A1Ionizable amine and ester lipids and lipid nanoparticlesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3560US12059477B2NanomaterialsBEAM THERAPEUTICS INC·Filed 2022·Granted Aug 13, 2024·0 cites·27 claims
- 3660US2024335541A1Nanomaterials comprising diaminesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3760US2024167008A1Novel crispr enzymes, methods, systems and uses thereofBEAM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3860US2024335385A1Ionizable amine lipids and lipid nanoparticlesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3960US2025092450A1Identification of nanoparticles for preferential tissue or cell targetingBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4059US2024287453A1Persistent allogeneic modified immune cells and methods of use thereofBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4159US2024301405A1Guide rnas for crispr/cas editing systemsBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4259US2024294914A1Compositions and methods for treating hepatitis b virus infectionBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4359US2024360433A1Compositions and methods for the treatment of hereditary angioedema (hae)BEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4459US2025213493A1Nanomaterials comprising triolsBEAM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4558US2026062704A1Compositions and methods for treating stargardt diseaseBEAM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4657US2023110201A1Pseudotyped recombinant lyssaviruses for gene therapyBEAM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4756US2023331657A1Nanomaterials comprising ester-linked acetalsBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4855US2023357133A1Nanomaterials comprising carbonatesBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4955US2022170027A1Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5055US2023242884A1Compositions and methods for engraftment of base edited cellsBEAM THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 85 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →